DV

Daniel Vitt

Chief Executive Officer

Immunic Therapeutics

Munich, Bavaria


Contact Information

Email
Unlock
LinkedIn

Company Information

Company
Immunic Therapeutics
Industry
research
Employees
84.0
Seniority
C suite
Annual Revenue
37500000.0

Technologies

Outlook Apache Mobile Friendly Etracker WordPress.org Piwik Basis Data Analytics

Keywords

healthcare biotechnology life sciences biotechnology: pharmaceutical preparations health care biotechnology research immunology oral therapies chronic inflammatory diseases autoimmune diseases vidofludimus calcium imu-856 imu-381 clinical trials multiple sclerosis celiac disease ulcerative colitis therapeutic efficacy safety & tolerability small molecule modulators neuroprotective effects dihydroorotate dehydrogenase dhodh inhibition sirtuin 6 sirt6 gastrointestinal diseases intestinal barrier function regeneration of bowel epithelium immune response clinical development phase 3 trials phase 2 trials first-in-class weight management patient needs therapeutic options chronic conditions pharmaceutical industry biopharmaceuticals research & development dosage forms patient-friendly health outcomes innovation drug development clinical data medical research therapeutics biotech solutions transformative healthcare chronic disease management patient care strategies safety profiles medical therapies health technology health wellness & fitness hospital & health care

Get Full Contact Details

Subscribe to reveal email addresses and export contacts.

View Plans